Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CV Therapeutics gets Ranexa tradename in the EU

This article was originally published in Scrip

Executive Summary

CV Therapeutics will be able to market its novel angina treatment ranolazine as Ranexa in Europe following approval of the brand name by theEMEA. The product was granted approval last month for use as Latixa as an add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled or are intolerant to first-line antianginal therapies. The Ranexa name is used in the product's first market, the US, allowing brand synergy across these two major markets, CV Therapeutics notes.

You may also be interested in...



Another Failure For Biohaven’s Troriluzole

Biohaven’s investigational glutamate modulator troriluzole did not improve symptoms in patients with mild-to-moderate disease, adding to the list of failures in Alzheimer’s disease, as well as for the product itself.

FDA Approval Opens Up Gastric Cancer To Daiichi Sankyo/AZ’s Enhertu

The two companies can now market their HER-2 targeting antibody-drug conjugate in its second tumor type as they look to expand beyond breast cancer.

Genmab/AbbVie’s Epcoritamab Advances As Deal Bears Fruit

The Danish company pockets $40m as the lead asset in the potential multi-billion dollar deal with AbbVie for bi-specific antibodies progresses into Phase III, and while it looks to build up its commercial infrastructure.

Topics

Related Companies

UsernamePublicRestriction

Register

PS051363

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel